Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues:
Contract revenue		$ 507,171	$ 33,351	$ 1,644,818
Revenues	$ 186,198	608,811	548,615	2,038,653
Cost of revenues	(166,265)	(386,641)	(492,942)	(1,579,485)
Gross profit	19,933	222,170	55,673	459,168
Operating expenses:
Research and development	2,481,296	1,266,527	5,953,568	6,136,743
General and administrative	914,019	768,420	2,720,739	2,422,863
Research and development expense - milestone				5,000,000
Total operating expenses	3,395,315	2,034,947	8,674,307	13,559,606
Loss from operations	(3,375,382)	(1,812,777)	(8,618,634)	(13,100,438)
Gain on forgiveness of PPP loan			421,584
Foreign currency transaction loss	(66,967)	(7,647)	(22,384)	(34,465)
Interest (expense) income	(216,800)	486	(645,055)	24,450
Research and development incentives	40,844	29,778	121,896	125,303
Other Income	30,754		30,754
Net loss before income taxes	(3,587,551)	(1,790,160)	(8,711,839)	(12,985,150)
Income tax benefit			864,742	836,893
Net loss applicable to common stockholders	$ (3,587,551)	$ (1,790,160)	$ (7,847,097)	$ (12,148,257)
Basic and diluted net loss per share (in Dollars per share)	$ (0.09)	$ (0.06)	$ (0.20)	$ (0.45)
Basic and diluted weighted average common shares outstanding (in Shares)	40,697,888	29,572,392	39,210,984	26,639,116
Grant
Revenues:
Revenue	$ 186,198	$ 101,640	$ 515,264	$ 393,835